SCHEMBL683652

SCHEMBL683652

Cn1cnc2c1c(=O)n(CN1CCN(c3cccc(Cl)c3)CC1)c(=O)n2C

nearest known ligand 0.55

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 3/20 0.55
ALDH1A1 P00352 5/20 0.53
SMN1; SMN2 Q16637 5/20 0.53
HTT P42858 3/20 0.53
LMNA P02545 3/20 0.52
TSHR P16473 3/20 0.52
GAA P10253 2/20 0.52
USP2 O75604 2/20 0.52
KDM4E B2RXH2 1/20 0.52
TNF P01375 1/20 0.52
GLA P06280 1/20 0.52
NOD2 Q9HC29 1/20 0.52
NOD1 Q9Y239 1/20 0.52
MAPT P10636 2/20 0.51
NPSR1 Q6W5P4 1/20 0.51
TP53 P04637 1/20 0.51
HTR1A P08908 2/20 0.49
HTR2A P28223 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL684026 0.90 MAPK1 (0.49) MAPK1ALDH1A1LMNATSHRUSP2
SCHEMBL684023 0.88 HTR2A (0.58) MAPK1ALDH1A1SMN1; SMN2HTTLMNA
SCHEMBL684068 0.88 ADORA2B (0.50) MAPK1TP53HTR1AHTR2A
SCHEMBL683653 0.88 ADRA1D (0.52) MAPK1SMN1; SMN2HTTLMNATSHR
SCHEMBL684377 0.87 MAPK1 (0.47) MAPK1ALDH1A1SMN1; SMN2TNFGLA
SCHEMBL683657 0.86 DRD2 (0.51) MAPK1ALDH1A1TSHRHTR1AHTR2A
SCHEMBL683667 0.86 ADORA2B (0.46) MAPK1SMN1; SMN2LMNATSHRUSP2
SCHEMBL683669 0.85 MAPK1 (0.45) MAPK1ALDH1A1SMN1; SMN2HTTGLA
SCHEMBL683665 0.84 ADORA2B (0.47) MAPK1SMN1; SMN2LMNATSHRUSP2
SCHEMBL683646 0.83 HTR2A (0.52) MAPK1SMN1; SMN2LMNATSHRUSP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110269717-A1 NEUROGENESIS BY MODULATING ANGIOTENSIN BRAINCELLS INC. (US) 2011-11-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110269717-A1 NEUROGENESIS BY MODULATING ANGIOTENSIN NGF, DCX, BDNF MAPK1 470/4885ALDH1A1 1565/4885SMN1; SMN2 907/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.